Literature DB >> 21820024

Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.

Anna Bershteyn1, Melissa C Hanson, Monica P Crespo, James J Moon, Adrienne V Li, Heikyung Suh, Darrell J Irvine.   

Abstract

New subunit vaccine formulations with increased potency are of interest to improve immune responses against poorly immunogenic antigens, to avoid vaccine shortages in pandemic situations, and to promote dose-sparing of potent adjuvant molecules that can cause unacceptable side effects in prophylactic vaccination. Here we report strong class-switched, high avidity humoral immune responses elicited by a vaccine system based on poly(lactide-co-glycolide) micro- or nano-particles enveloped by PEGylated phospholipid bilayers, with protein antigens covalently anchored to the lipid surface and lipophilic adjuvants inserted in the bilayer coating. Strikingly, these particles elicited high endpoint antigen-specific IgG titers (>10(6)) sustained for over 100 days after two immunizations with as little as 2.5 ng of antigen. At such low doses, the conventional adjuvant alum or the molecular adjuvants monophosphoryl lipid A (MPLA) or α-galactosylceramide (αGC) failed to elicit responses. Co-delivery of antigen with MPLA or αGC incorporated into the particle bilayers in a pathogen-mimetic fashion further enhanced antibody titers by ~12-fold. MPLA provided the highest sustained IgG titers at these ultra-low antigen doses, while αGC promoted a rapid rise in serum IgG after one immunization, which may be valuable in emergencies such as disease pandemics. The dose of αGC required to boost the antibody response was also spared by particulate delivery. Lipid-enveloped biodegradable micro- and nano-particles thus provide a potent dose-sparing platform for vaccine delivery. Copyright Â
© 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820024      PMCID: PMC3811132          DOI: 10.1016/j.jconrel.2011.07.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  78 in total

1.  Cationic microparticles: A potent delivery system for DNA vaccines.

Authors:  M Singh; M Briones; G Ott; D O'Hagan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  CpG motifs as immune adjuvants.

Authors:  D M Klinman; K M Barnhart; J Conover
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

3.  Differential levels of dendritic cell maturation on different biomaterials used in combination products.

Authors:  Julia E Babensee; Abhijit Paranjpe
Journal:  J Biomed Mater Res A       Date:  2005-09-15       Impact factor: 4.396

Review 4.  Nanotoxicity: the growing need for in vivo study.

Authors:  Hans C Fischer; Warren C W Chan
Journal:  Curr Opin Biotechnol       Date:  2007-12-21       Impact factor: 9.740

5.  Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  R Shahin; M Leef; J Eldridge; M Hudson; R Gilley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

Review 6.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

7.  The influence of intestinal processing on the immunogenicity and molecular size of absorbed, circulating ovalbumin in mice.

Authors:  M G Bruce; A Ferguson
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

8.  Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A.

Authors:  G M Glenn; M Rao; R L Richards; G R Matyas; C R Alving
Journal:  Immunol Lett       Date:  1995 Jul-Aug       Impact factor: 3.685

9.  Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA.

Authors:  M Singh; G Ott; J Kazzaz; M Ugozzoli; M Briones; J Donnelly; D T O'Hagan
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.580

10.  Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues.

Authors:  Daniel J Campbell; Eugene C Butcher
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  40 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 2.  Particle based vaccine formulations for transcutaneous immunization.

Authors:  Ankit Mittal; Anne S Raber; Claus-Michael Lehr; Steffi Hansen
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

3.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 4.  Biomimetic and synthetic interfaces to tune immune responses.

Authors:  Anusha Garapaty; Julie A Champion
Journal:  Biointerphases       Date:  2015-09-15       Impact factor: 2.456

5.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

Review 6.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

7.  Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions.

Authors:  Iris R Bell; John A Ives; Wayne B Jonas
Journal:  Dose Response       Date:  2013-11-07       Impact factor: 2.658

8.  Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.

Authors:  Sarah N Mueller; Shaomin Tian; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2015-04-08       Impact factor: 4.939

9.  Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs.

Authors:  Rebecca R Pompano; Jianjun Chen; Emily A Verbus; Huifang Han; Arthur Fridman; Tessie McNeely; Joel H Collier; Anita S Chong
Journal:  Adv Healthc Mater       Date:  2014-06-13       Impact factor: 9.933

10.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.